Eucreas

ildagliptin: This is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones in the body. Incretins stimulate the release of insulin and inhibit the production of glucagon, both of which help lower blood sugar levels.

Metformin: Metformin is a biguanide medication that improves the sensitivity of body tissues to insulin, reducing the amount of glucose produced by the liver and enhancing the uptake of glucose by cells.

Indications: Eucreas is indicated for the treatment of type 2 diabetes in adults. It is typically prescribed when blood sugar control is not achieved with metformin alone.

Combination Therapy: Combining vildagliptin and metformin in Eucreas provides a dual mechanism of action to improve blood sugar control. It addresses insulin resistance and reduces the production of glucose by the liver.

Dosage: The dosage of Eucreas will be determined by a healthcare provider based on the individual's specific needs and response to treatment. It is usually taken orally with meals to reduce the risk of gastrointestinal side effects.

Side Effects: Common side effects of Eucreas may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially when Eucreas is used in combination with other diabetes medications.

Monitoring: Regular monitoring of blood sugar levels and periodic assessments of kidney function are typically recommended during treatment with Eucreas.

Contraindications: Eucreas is contraindicated in individuals with severe renal impairment, acute conditions that may affect kidney function, and certain other medical conditions. It's important to inform the healthcare provider about any existing health conditions or medications being taken.